HKEX Filings
-
Mar 18, 2022
CLARIFICATION ANNOUNCEMENT
-
Mar 17, 2022VOLUNTARY ANNOUNCEMENT - CLOVER'S COVID-19 VACCINE CANDIDATE DEMONSTRATED DURABLE HIGH PROTECTION AND STRONG IMMUNE RESPONSE AGAINST OMICRON AS A BOOSTER
-
Mar 17, 2022DATE OF BOARD MEETING
-
Mar 11, 2022CHANGE OF ADDRESS OF HEADQUARTERS IN THE PRC
-
Mar 4, 2022Monthly Return of Equity Issuer on Movements in Securities for the Month ended February 28, 2022
-
Feb 24, 2022VOLUNTARY ANNOUNCEMENT - INCLUSION ON THE HANG SENG COMPOSITE INDEX
-
Feb 14, 2022VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE
-
Feb 7, 2022Monthly Return of Equity Issuer on Movements in Securities for the Month ended January 31, 2022
-
Jan 28, 2022WAIVER FROM STRICT COMPLIANCE WITH RULE 10.07(1)(B) OF THE LISTING RULES
-
Jan 21, 2022VOLUNTARY ANNOUNCEMENT - PUBLICATION IN THE LANCET SHOWING THAT SCB-2019 (CPG 1018/ALUM) IN A PHASE 2/3 CLINICAL TRIAL DEMONSTRATES EFFICACY AGAINST ENTIRE SEVERITY SPECTRUM OF COVID-19
-
Jan 6, 2022Monthly Return of Equity Issuer on Movements in Securities for the Month ended December 31, 2021
-
Jan 5, 2022VOLUNTARY ANNOUNCEMENT - DOSING OF FIRST PARTICIPANTS WITH HOMOLOGOUS BOOSTER DOSE OF COVID-19 VACCINE CANDIDATE IN SPECTRA
-
Dec 22, 2021CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
-
Dec 9, 2021VOLUNTARY ANNOUNCEMENT - COLLABORATION AGREEMENT WITH ASCENTAGE PHARMA
-
Dec 7, 2021VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE VACCINE SUPPLY AGREEMENT
-
Dec 6, 2021Monthly Return of Equity Issuer on Movements in Securities for the Month ended November 30, 2021
-
Nov 29, 2021STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF OVER-ALLOTMENT OPTION
-
Nov 26, 2021VOLUNTARY ANNOUNCEMENT COVID-19 VACCINE CANDIDATE ADMINISTERED AS HETEROLOGOUS BOOSTER IN INVESTIGATOR-LED PHASE 2 CLINICAL TRIAL
-
Nov 26, 2021DISCLOSEABLE TRANSACTION IN RELATION TO THE LEASE AGREEMENT
-
Nov 18, 2021VOLUNTARY ANNOUNCEMENT AMENDMENT TO CEPI FUNDING AGREEMENT
